Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2010

View Archived Issues

GlaxoSmithKline presents new calcium receptor antagonists

Pfizer describes novel AMPA receptor agonists

Humoral responses to DC-Melvac cancer vaccine seen in melanoma patients

Hepatitis C treatment SCY-635 associated with a high barrier to resistance

INT-747 promising as add-on therapy to ursodeoxycholic acid for primary biliary cirrhosis

Updated phase I data disclosed on IMO-2125 in HCV infection

EMD-1214063 displays potent and selective c-Met inhibition

Telik presents novel Aurora A/B and VEGFR-2 inhibitors

Dual TLR7 and TLR9 antagonist has therapeutic effects in mouse model of atherosclerosis

New FAAH inhibitors claimed by Renovis

Novartis reports R&D highlights for first quarter of 2010

Temozolomide shows activity in pituitary tumors and carcinomas

Oncolytics Biotech completes phase I enrollment for phase I/II Reolysin trial

FDA recommends reformulation of UCB's Neupro

Nycomed and Merck & Co. collaborate on commercialization of roflumilast in Canada and Europe

EMA's CHMP recommends extending indication of tocilizumab

ALK to acquire Fornix Biosciences' allergy division in The Netherlands

Penwest provides update on focused business plan

CHMP recommends Seroquel XR as add-on treatment for major depressive disorder

New FDA initiative to reduce risks related to infusion pumps

Presidio and Numerate end HCV research collaboration

Michael J. Fox Foundation awards grants to advance Parkinson's disease research

Stem Cell Therapeutics completes 90-day endpoint period for REGENESIS trial

ACT completes studies to support phase I stem cell trial in SMD

AD-02 Alzheimer's vaccine progresses to phase II

CHMP recommends conditional marketing approval for Votrient

Proteo completes patient recruitment in phase II Elafin trial

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Astellas’ ASP-2246 shows promise in stroke management
BioWorld Science
Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...